Back to catalogue
№ 058 9 filings · 2023-11-10 → 2026-03-30

BIOVENTIX PLC

BVXP
Health Care Market cap £87m Overall fit 360 /1000

High-quality, fair-priced, very high operating leverage and strong downside protection, but essentially zero AI-receiver exposure means it fails the investor's primary pillar; placed in 'partial fit' band.

Fair value range 1,700p–2,050p Mid case · £98m
Absolute upside +13% vs current market cap
Conviction 4/5 confidence in fair call
Supports the call
  • Simple, clean FRS 102 royalty-model disclosure across 5 years
  • P/E and dividend-yield approaches converge on ~£90-100m
  • Net cash, no debt, no acquisitive noise
Limits the call
  • Alzheimer's IVD timing and royalty-share unsized in filings
  • FY25 final-dividend cut signals management caution on core
Methodology

Blended P/E (12-15x FY26E EPS ~140p) and yield support (~7-8% on ~150p DPS)

In one line · bull case

Capital-light, high-margin antibody royalty business with embedded customer relationships, paying an ~8% yield while offering free optionality on Alzheimer's blood-test IVD approvals where Bioventix SMAs are already designed into multiple platforms.

In one line · biggest risk

Mature core revenue continues to erode (vitamin D, China, troponin) faster than Tau/neuro royalties scale, leaving the dividend funded from reserves rather than profit growth.

Drivers
AI beneficiary 8 /100
Diagnostic antibody royalty business — no meaningful exposure to AI buildout or agentic-AI adoption.
Operating leverage 82 /100
91.7% gross margin, ~£1.5m fixed cost base on £6m H1 revenue; incremental Tau royalties drop ~80%+ to profit.
Earnings vs expectations 45 /100
Mostly meets management's own (progressively lowered) guidance; troponin has repeatedly disappointed the prior bull case.
Growth momentum 32 /100
Revenue flat-to-down for 3 reporting periods; Tau royalties growing fast but off a tiny base.
Moat 75 /100
SMAs are designed into multiple Roche/Siemens/Abbott/Beckman immunoassays — high regulatory switching costs once embedded.
Earnings quality 85 /100
Royalty income with very strong cash conversion (H1 FY26 operating cash £4.4m on £3.6m PAT); no goodwill, no acquisitions.
Management quality 72 /100
Long-tenured CEO, candid disclosure, disciplined capital return; CardiNor impairment and 'use of reserves' language signal honesty.
Cyclicality 15 /100
Routine clinical diagnostics demand is highly defensive; only Chinese channel softness has bitten recently.
Leverage 5 /100
Net cash of £5.3m, no debt, freehold property — fortress balance sheet.
Value-trap signals · 4
  • Core revenue flat-to-declining for three reporting periods
  • Single-customer royalty concentration disclosed in accounting policy
  • FY25 final dividend cut vs FY24; FY26 interim held flat, not raised
  • China revenue streams explicitly lost

BIOVENTIX PLC (BVXP) — Investment Research Note

Executive summary

Bioventix is a Farnham-based developer and royalty-licensor of sheep-derived high-affinity monoclonal antibodies (SMAs) that sit embedded inside the immunoassays of the world's major in-vitro diagnostics (IVD) companies (Roche, Siemens, Abbott, Beckman et al.), with vitamin D as the legacy cash cow and a maturing Alzheimer's/neurology pipeline (Tau, pT217) as the only growth lever. Trading across FY24–H1 FY26 shows a mature core (revenue flat-to-down, H1 FY26 revenue −8.5% to £6.16m, PBT −4% to £4.85m) being slowly supplemented by Tau royalties (£150k vs £30k yoy, 5×), while the company continues to distribute essentially all profits as dividends. The single most important valuation point is whether/when Tau-based blood tests for Alzheimer's transition from research-use-only to approved IVD assays — Bioventix SMAs are already designed into multiple leading platforms, but the timing and royalty economics of that transition are unknown.

Fair value estimate

  • Fair value range: 1,700p – 2,050p per share (mid ~1,875p)
  • Implied market cap range: £89m – £107m (mid ~£98m)
  • Methodology: blended P/E + dividend-yield support.
    • P/E: H1 FY26 basic EPS 69.4p 2026-03 interim suggests FY26 EPS of ~135–140p (H2 typically modestly weaker on FX/R&D phasing). Applying 12–15x P/E (justified by 90%+ gross margins, fortress balance sheet, embedded customer relationships, but capped by mature core and uncertain Alzheimer's timing) gives ~1,620p–2,100p.
    • Yield: H1 FY26 interim 70p + likely ~80p final = ~150p FY26 dividend 2026-03 interim cash-flow statement showing £4.18m FY25 final paid in H1 FY26 ÷ ~5.22m shares ≈ 80p. At a 7–8% "fair" yield for a mature AIM cash-cow with declining dividend trajectory, that supports 1,875p–2,140p.
  • Current market cap £90.1m sits at the bottom of this range. Absolute upside to mid ≈ +8–10%, with negligible downside given net cash and the dividend.

Sector context

  • ICB classification confirmed: Health Care (specialty diagnostics / antibody supplier).
  • Quality is above-sector (90%+ gross margins, net cash, royalty model), growth is below-sector (essentially flat for 3+ years), leverage is below-sector (net cash of £5.3m).
  • Closest listed peers: Abcam (pre-Danaher takeover) was the most direct comparison — research-antibody supplier — though now private. Genus (animal genetics, royalty-like model) and small IVD suppliers like EKF Diagnostics provide loose read-across. None are clean peers; Bioventix is sui generis.

Investment thesis

  1. Genuine pricing-power moat embedded in customer assay designs. Once a Bioventix SMA is designed into a Roche/Siemens/Abbott immunoassay, regulatory re-validation makes substitution economically prohibitive. The H1 FY26 statement notes Bioventix SMAs are now in three major IVD pT217 designs, three high-sensitivity Alzheimer's platforms, four IVD total-Tau designs, and four high-sensitivity total-Tau platforms 2026-03 interim. This is an unusually deep embedment for a ~£90m company.
  2. Asymmetric Alzheimer's optionality at no incremental cost. Tau/neuro royalties went from £30k to £150k yoy on RuO assays alone; management explicitly states future IVD approvals "will materialise in tangible commercial success" 2026-03 interim. With 90%+ gross margins and a tiny fixed cost base, even modest IVD ramps drop almost entirely to profit.
  3. Capital-return discipline + fortress balance sheet floor. Net cash, no debt, ~8.5% trailing dividend yield, interim dividend held at 70p despite H1 EPS dip 2026-03 interim. The yield alone provides material downside protection.

Key risks

  1. Vitamin D and core franchise are in slow structural decline. China weakness has cost "some limited revenue streams" 2026-03 interim, and core sales are explicitly described as reflecting "the mature nature of the diagnostic products that our core antibodies support". Without Tau, the cash flow base erodes.
  2. Troponin upside has repeatedly disappointed. Siemens FDA prognostic-label approval flagged Nov-2024 has still produced "no uplift" by H1 FY26 2026-03 interim; flagged as below expectations in 2025-03 and 2024-03 interims too. Management's "wait and see" stance suggests the bull case for troponin remains aspirational.
  3. Alzheimer's IVD timing risk and royalty-share uncertainty. Management itself states "the timing of these future IVD assay developments is difficult to predict" 2026-03 interim and they face "competing antibodies … from other respected sources in addition to antibodies created in-house by our IVD company partners" 2024-03 interim. Multiple-customer designs are encouraging but not exclusive.

Operating leverage

This is a near-textbook high-operating-leverage business. H1 FY26 gross margin was 91.7% (£5.65m / £6.16m) and the entire operating cost base below gross profit is roughly £1.5m fixed (£1.04m admin, ~£0.5m of R&D net of credit, share-option non-cash) 2026-03 interim. Headcount is small; the Farnham facility is freehold; depreciation runs at <£60k/yr. Incremental contribution margin is essentially the gross margin (~90%+) less royalty-revenue–linked R&D, which is now structured "as a small percentage of the future revenue generated by SMAs in neurological assays" 2026-03 interim — so even that variable share is modest. If Tau royalties scale to, say, an additional £2m, operating profit would rise by roughly £1.7–1.9m (~35–40% uplift on the current ~£4.8m H1 run-rate). A 10–20% revenue surprise from Alzheimer's IVD wins would plausibly drop ~80% to operating profit — exactly the long-tail dynamic the investor wants. The constraint is not leverage but the probability of the revenue surprise.

Value-trap signals

  • Core revenue mature/declining. Flat-to-down for three reporting periods; China explicitly cited as a drag.
  • Customer concentration. Royalty revenue notably accrued from "one customer on a calendar year basis annually in arrears" 2026-03 interim Note 3, indicating one single dominant licensee (long understood to be Siemens vitamin D).
  • Dividend has stopped growing. FY26 interim held flat at 70p 2026-03 interim after years of low-single-digit increases; FY25 final implied ~80p vs FY24 final ~87p — a cut in final, masked by held interim. Management language about using "reserves to maintain our dividend at historic levels" is a soft warning.
  • Investments written down. CardiNor AS impaired in FY24; Pre-Diagnostics carried at historic cost with disclosure that fair value cannot be reliably determined 2025-03 and 2026-03 interim Note 3.

Earnings vs. expectations

The pattern is mostly in line, slight downward drift. H1 FY24 was the only clear beat with revenue +13% yoy and PBT +16%, driven by China 2024-03 interim. H1 FY25 was "in line" (revenue +1%, PBT −4%, with R&D step-up the stated cause) and guidance was reset for FY25 to be "similar to" FY24 2025-03 interim. H1 FY26 then came in below H1 FY25 on both revenue (−8.5%) and PBT (−4%), again described as "in line with expectations" — i.e. expectations have been progressively lowered 2026-03 interim. There is no visible analyst consensus referenced in filings. Net: management is candid and rarely misses its own guidance, but the direction of guidance has been downward, and troponin has repeatedly disappointed the bull case.

Conviction

4 — high. Anchored by: (1) very clean, simple FRS 102 disclosure with consistent line items across 5 years; (2) a single-customer-royalty business model with no acquisition noise, no goodwill, no debt; (3) two valuation approaches (P/E and yield) converge on roughly the same £90–100m fair-value cluster. Limited by: (1) the Alzheimer's optionality is real but unsized — the right-tail of fair value is dependent on regulatory and royalty-share assumptions the filings cannot pin down; (2) the FY25 final-dividend cut and "use of reserves" language hint at management's own caution about near-term core decline.

Fit to investor profile

This is high quality but largely outside the AI thesis. Bioventix has zero meaningful AI-receiver exposure — diagnostics antibody royalties don't get more valuable because hyperscalers build data centres or enterprises buy Copilots. The operating-leverage characteristic is excellent and the valuation is fair-to-slightly-cheap with strong downside protection from net cash + dividend, but the missing AI pillar caps the overall score. A reasonable holding for a defensive, yield-aware sleeve of the book, but not a strategy-fit name.

Filings consulted · 9

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-03-30Interim Results2026-03-30_9496897_interim-results.md0.90
  2. 2025-12-04Result OF Agm2025-12-04_9276823_result-of-agm.md0.30
  3. 2025-11-11Posting OF Annual Report And Notice OF Agm2025-11-11_9225028_posting-of-annual-report-and-notice-of-agm.md0.81
  4. 2025-03-31Interim Results2025-03-31_8804119_interim-results.md0.58
  5. 2024-12-06Result OF Agm2024-12-06_8594138_result-of-agm.md0.20
  6. 2024-11-08Notice OF Agm2024-11-08_8538119_notice-of-agm.md0.20
  7. 2024-03-25Interim Results2024-03-25_8103604_interim-results.md0.41
  8. 2023-12-07Result OF Agm2023-12-07_7928960_result-of-agm.md0.14
  9. 2023-11-10Posting OF Annual Report And Notice OF Agm2023-11-10_7874618_posting-of-annual-report-and-notice-of-agm.md0.43

This research note was authored by a large language model after reading 9 regulatory filings published between 2023-11-10 and 2026-03-30. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.